晚期宫颈癌免疫再挑战应答的时空免疫决定因素
这项多中心单臂II期试验纳入30例既往ICI治疗后进展的晚期宫颈癌患者,接受zimberelimab联合仑伐替尼再挑战治疗。单细胞多组学分析显示应答者CD8+ T细胞毒性表型增强,非应答者外周血出现NK样CD8+ T和祖耗竭CD8+ T表型,肿瘤中CD45+CD3+Lyz+双联细胞与临床获益相关。
要点
- 免疫再挑战对既往ICI进展的晚期宫颈癌可能有效。
- 应答者CD8+ T细胞毒性表型增强且耗竭减少。
- CD45+CD3+Lyz+双联细胞与临床获益相关。
核心结论
- 免疫再挑战可能对既往ICI治疗后进展的晚期宫颈癌患者有效。
研究设计与样本
- 多中心单臂II期试验(NCT05824468)纳入30例既往ICI治疗中或后进展的晚期宫颈癌患者。
- 患者接受zimberelimab联合仑伐替尼再挑战治疗。
- 对复发肿瘤连续活检和外周血样本进行单细胞多组学分析。
主要发现
- 应答者CD8+ T细胞呈现更强的细胞毒性表型。
- 非应答者外周血出现NK样CD8+ T和祖耗竭CD8+ T表型。
- 应答者肿瘤中效应记忆CD8+ T细胞增多、耗竭CD8+ T细胞减少。
- CD45+CD3+Lyz+双联细胞(T细胞与髓系细胞组成)与临床获益相关。
临床怎么用
- 时空基因组和免疫学改变可作为未来临床实践中识别再挑战应答者的治疗生物标志物。
局限性
- 单臂设计且样本量较小(30例)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: Although immune checkpoint inhibitors (ICI) show durable responses in various cancers, relapse remains common. The efficacy of retreatment with ICIs is controversial. We conducted a multicenter, single-arm, phase II trial (NCT05824468), including 30 patients with advanced cervical cancer who experienced disease progression on or after prior ICI therapy. Participants received a combined regimen of zimberelimab and lenvatinib (immune rechallenge). Single-cell multiomics analysis of sequential biopsies of relapsed tumors and blood samples showed that immune rechallenge induced a more cytotoxic phenotype in CD8+ T cells in responders, whereas a natural killer-like CD8+ T and progenitor-exhausted CD8+ T phenotype was observed in the blood of nonresponders. In tumors, responders showed more effector memory CD8+ T cells and reduced exhausted CD8+ T cells after treatment. A population of CD45+CD3+Lyz+ dyad cells, composed of T cells and myeloid cells, was correlated with clinical benefit. Our findings proved that immune rechallenge could be an effective treatment for patients with advanced cervical cancer whose disease progressed on or after prior ICI therapy. SIGNIFICANCE: This study highlights response heterogeneity within patients with advanced cervical cancer with progressive disease on prior ICIs to immune rechallenge and underscores its potential feasibility. Spatiotemporal genomic and immunologic alterations are critical treatment biomarkers to identify responders in future clinical practice.
引用
- Lan C, Zhang P, Zhao J, et al. Spatiotemporal Immune Determinants of Response to Immune Rechallenge in Advanced Cervical Cancer. Cancer Discov. 2026. PMID: 41511850. doi:10.1158/2159-8290.CD-25-0467
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。